NASDAQ · CYCN
Cyclerion Therapeutics, Inc.
$23.52$0.00 (0.0%)
Cyclerion Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.38% below the high.
Loading market information…
OTC · BXRXQ · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Baudax Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Baudax Bio, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$270.67. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Baudax Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2015 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$23.52$0.00 (0.0%)
Cyclerion Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.38% below the high.
$1.22-$0.02 (-1.61%)
Cellectar Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.04% below the high.
$8.72-$0.03 (-0.29%)
Moleculin Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.23% below the high.
$0.19-$0.01 (-6.25%)
GeoVax Labs, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.72% below the high.
$0.14-$0.01 (-6.67%)
Hepion Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.36% below the high.
$0.03$0.00 (0.0%)
Acro Biomedical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 74.0% below the high.
$0.01$0.00 (0.0%)
NKGen Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.56% below the high.
$0.39-$0.00 (-0.94%)
Bone Biologics Corporation’s quoted price sits in the lower half of its reported 52-week range, 83.75% below the high.
